Oncolytic viruses (OVs) are an emerging class of cancer therapeutics that offer the benefits
of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads …

Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

Many mammalian viruses have properties that can be commandeered for the treatment of
cancer. These characteristics include preferential infection and replication in tumor cells, the …

Oncolytic viruses (OVs) are viral strains that can infect and kill malignant cells while spare
their normal counterparts. OVs can access cells through binding to receptors on their surface …

Lung cancer remains the leading cause of cancer-related deaths worldwide. However,
significant progress has been made individualizing therapy based on molecular aberrations …

Simple Summary Within this review article the authors provide an unbiased review of the
oncolytic virus, reovirus, clinically formulated as pelareorep. In particular, the authors …

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with 1 and 5-year survival
rates of~ 18% and 7% respectively. FOLFIRINOX or gemcitabine in combination with nab …

Oncolytic viruses (OVs) are emerging cancer therapeutics that offer a multifaceted
therapeutic platform for the benefits of replicating and lysing tumor cells, being engineered …

The success of antibodies targeting Programmed cell death protein 1 (PD-1) and its ligand
L1 (PD-L1) in cancer treatment and the need for improving response rates has led to an …

It has been intensively reported that the immunosuppressive tumor microenvironment (TME)
results in tumor resistance to immunotherapy, especially immune checkpoint blockade and …